Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

Faron Pharmaceuticals OyAnnouncement

Yesterday 14:30

Faron Pharmaceuticals Ltd | Company announcement | December 17, 2025 at
16:30:00 EET

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on tackling cancers via novel
immunotherapies, today announces that the following members have been
re-elected by a meeting of the Company's five largest shareholders to Faron
Pharmaceuticals Ltd’s Shareholders' Nomination Board:

* Timo Syrjälä, representing himself (Chair)
* Erkka Kohonen, representing Varma Mutual Pension Insurance Company, and
* Joonas Haakana, representing UMO Capital

Faron’s Shareholders' Nomination Board consists of three members, which
represent the Company's shareholders. The Chair of Faron’s Board of Directors,
Mr. Tuomo Pätsi, will serve as an expert in the Nomination Board without being
a member.

The Shareholders' Nomination Board prepares and presents proposals to the
Annual General Meeting on the number, composition and remuneration of the
members of the Board as well as the Chair of the Board of Directors.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                     +1 847 791-8085  |
| (Media)                             |        alyssa.paldo@finnpartners.com |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                 +44 (0) 207 213 0880 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                  +358 (0)40 555 4727 |
| (Certified Adviser on Nasdaq First  |                  +358 (0)50 553 8990 |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The company’s lead asset, bexmarilimab, is a novel
macrophage-guiding immunotherapy being investigated in multiple oncology
settings. Further information is available at www.faron.com
(http://www.faron.com/)